Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial. (Record no. 25818768)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02177 a2200673 4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250517084108.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 201610s 0 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 2044-5385 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1038/bcj.2016.9 |
| Source of number or code | doi |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | NLM |
| Language of cataloging | eng |
| Transcribing agency | NLM |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Bühler, A |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 20161013 |
| 245 00 - TITLE STATEMENT | |
| Title | Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial. |
| Medium | [electronic resource] |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Name of publisher, distributor, etc. | Blood cancer journal |
| Date of publication, distribution, etc. | Mar 2016 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | e404 p. |
| Other physical details | digital |
| 500 ## - GENERAL NOTE | |
| General note | Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Aged |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Aged, 80 and over |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antineoplastic Agents |
| General subdivision | therapeutic use |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Drug Resistance, Neoplasm |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Female |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Follow-Up Studies |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Humans |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Immunoglobulin Heavy Chains |
| General subdivision | genetics |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Immunologic Factors |
| General subdivision | therapeutic use |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Lenalidomide |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Leukemia, Lymphocytic, Chronic, B-Cell |
| General subdivision | diagnosis |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Male |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Middle Aged |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Mutation |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Prognosis |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Recurrence |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Retreatment |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Survival Analysis |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Thalidomide |
| General subdivision | analogs & derivatives |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Treatment Outcome |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Tumor Suppressor Protein p53 |
| General subdivision | genetics |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Wendtner, C-M |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Kipps, T J |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Rassenti, L |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Fraser, G A M |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Michallet, A-S |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Hillmen, P |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Dürig, J |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Gregory, S A |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Kalaycio, M |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Aurran-Schleinitz, T |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Trentin, L |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Gribben, J G |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Chanan-Khan, A |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Purse, B |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Zhang, J |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | De Bedout, S |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Mei, J |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Hallek, M |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Stilgenbauer, S |
| 773 0# - HOST ITEM ENTRY | |
| Title | Blood cancer journal |
| Related parts | vol. 6 |
| -- | p. e404 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://doi.org/10.1038/bcj.2016.9">https://doi.org/10.1038/bcj.2016.9</a> |
| Public note | Available from publisher's website |
No items available.